Sobi’s Aspaveli (pegcetacoplan) Receives NICE Recommendation for the Treatment of Paroxysmal Nocturnal Haemoglobinuria

Published: Dec 10, 2021 | Tags: Sobi, Aspaveli, pegcetacoplan, NICE, Paroxysmal Nocturnal Haemoglobinuria

Genentech Reports Results of Tiragolumab + Tecentriq (atezolizumab) in P-II (CITYSCAPE) Trial for the Treatment of NSCLC

Published: Dec 10, 2021 | Tags: Genentech, Tiragolumab, Tecentriq, atezolizumab, P-II, CITYSCAPE Trial, NSCLC

Thermo Fisher’s Oncomine Dx Target Test Receives the US FDA's Approval as a NGS-Based CDx for the Treatment of NSCLC

Published: Dec 10, 2021 | Tags: Thermo Fisher, Oncomine Dx Target Test, US, FDA, Approval, NGS-Based CDx , NSCLC

Vifor and Angion Report Results of ANG-3777 in P-II (GUARD) Trial for Cardiac Surgery Associated Acute Kidney Injury

Published: Dec 10, 2021 | Tags: Vifor, Angion, ANG-3777, P-II, GUARD, Trial, Cardiac Surgery, Acute Kidney Injury

Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal Carcinomatosis

Published: Dec 10, 2021 | Tags: Ascentage Pharma, Clover, APG-1387, SCB-313, Peritoneal Carcinomatosis

uniQure and CSL Behring Report Results of P-III (HOPE-B) Trial of Etranacogene Dezaparvovec for the Treatment of Hemophilia B

Published: Dec 10, 2021 | Tags: uniQure, CSL Behring, P-III, HOPE-B Trial, Etranacogene Dezaparvovec, Hemophilia B

Takeda Publishes the Results of Livtencity (maribavir) in P-III (SOLSTICE) Trial for Post-Transplant Patients with Cytomegalovirus Infection in CID

Published: Dec 9, 2021 | Tags: Takeda, Livtencity, maribavir, P-III, SOLSTICE Trial, Post-Transplant, Cytomegalovirus Infection, CID

Brii Bio’s Amubarvimab + Romlusevimab Receives NMPA’s Approval for the Treatment of COVID-19

Published: Dec 9, 2021 | Tags: Brii Bio, Amubarvimab, Romlusevimab, NMPA, Approval, COVID-19

AstraZeneca's Evusheld (AZD7442) Receives the US FDA's EUA for Pre-Exposure Prophylaxis of COVID-19

Published: Dec 9, 2021 | Tags: AstraZeneca, Evusheld, AZD7442, US, FDA, EUA, Pre-Exposure Prophylaxis, COVID-19

Qiagen Collaborates with Denovo Biopharma to Develop CDx Test for the Treatment of Diffuse Large B-Cell Lymphoma

Published: Dec 9, 2021 | Tags: Qiagen, Denovo Biopharma, CDx Test, Diffuse Large B-Cell Lymphoma

Checkpoint Reports the Initiation of P-III (CONTERNO) Trial for Cosibelimab as 1L Treatment of Non-Squamous NSCLC

Published: Dec 9, 2021 | Tags: Checkpoint, P-III, CONTERNO, Trial, Cosibelimab, Non-Squamous NSCLC

MSD Entered into a Clinical Trial Collaboration with SOTIO to Evaluate SOT101 + Keytruda (pembrolizumab) for the Treatment of Solid Tumors

Published: Dec 9, 2021 | Tags: MSD, SOTIO, SOT101, Keytruda, pembrolizumab, Solid Tumors

Sage and Biogen Presents Results of Zuranolone in LANDSCAPE Clinical Program for Major Depressive Disorder at ACNP 2021

Published: Dec 8, 2021 | Tags: Sage, Biogen, Zuranolone, LANDSCAPE, Clinical Program, Major Depressive Disorder, ACNP 2021

Roche’s Actemra/RoActemra Receives EC’s Approval for the Treatment of Severe COVID-19

Published: Dec 8, 2021 | Tags: Roche, Actemra, RoActemra, EC, Approval, COVID-19

Neurocrine Reports Results of Valbenazine in P-III (KINECT-HD) Study for the Treatment of Chorea Associated with Huntington Disease

Published: Dec 8, 2021 | Tags: Neurocrine, Valbenazine, P-III, KINECT-HD Study, Chorea, Huntington Disease

GSK and Medicago Reports Results of COVID-19 Vaccine in P-III Study for the Treatment of COVID-19

Published: Dec 8, 2021 | Tags: GSK, Medicago, COVID-19, Vaccine, P-III, Study, COVID-19

Recursion Collaborates with Roche and Genentech to Advance Novel Therapeutic Programs in Neuroscience and Oncology

Published: Dec 8, 2021 | Tags: Recursion, Roche, Genentech, Therapeutic Programs , Neuroscience, Oncology

Alvotech Going Public via Oaktree SPAC Merger for ~$2.25B

Published: Dec 8, 2021 | Tags: Alvotech, Going Public, Oaktree, SPAC, Merger, ~$2.25B

Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine

Published: Dec 7, 2021 | Tags: Biohaven, Zavegepant, P-III, Study, Migraine

Aerie Signs an Exclusive Agreement with Santen for Rhopressa and Rocklatan to Treat Glaucoma or Ocular Hypertension in EU and Other Countries

Published: Dec 7, 2021 | Tags: Aerie, Santen, Rhopressa, Rocklatan, Glaucoma, Ocular Hypertension, EU

AstraZeneca Entered into a Collaboration Agreement with Ionis to Develop and Commercialize Eplontersen for the Treatment of Transthyretin Amyloidosis

Published: Dec 7, 2021 | Tags: AstraZeneca, Ionis, Eplontersen, Transthyretin Amyloidosis

Merck Entered into Clinical Trial Collaboration with Carisma to Evaluate Keytruda (pembrolizumab) + CAR-M for HER2 Positive Cancers

Published: Dec 7, 2021 | Tags: Merck, Carisma, Keytruda, pembrolizumab, CAR-M, HER2 Positive Cancers

Merck Pauses Enrollment in P-III (IMPOWER 22) and (IMPOWER 24) Clinical Trial of Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection

Published: Dec 7, 2021 | Tags: Merck, P-III, IMPOWER 22, IMPOWER 24, Clinical Trials, Islatravir, Pre-Exposure Prophylaxis, HIV-1 infection

AbbVie’s Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEED) Induction Study for the Treatment of Crohn's Disease

Published: Dec 7, 2021 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, U-EXCEED, Induction Study, Crohn's Disease

Aeglea Biotherapeutics Achieves Primary Endpoint in P-III study of Pegzilarginase in patients with Arginase 1 Deficiency

Published: Dec 6, 2021 | Tags: Aeglea, Pegzilarginase, ARG-1D, Arginase 1 Deficiency, PEACE, GMFM-E, USFDA, Results

Bavarian Nordic Plans to Initiate P-III Trial of Respiratory Syncytial Virus Candidate MVA-BN

Published: Dec 6, 2021 | Tags: Bavarian Nordic, MVA-BN; RSV, Respiratory Syncytial Virus, Vaccine

J&J’s Vaccine Booster Dose Increases Antibody & T-cell Responses 6 mos Post BNT162B2 Regimen

Published: Dec 6, 2021 | Tags: J&J, US, FDA, Booster Dose; BNT162B2, COVID-19

Jacobio Receives CDE’s IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Published: Dec 6, 2021 | Tags: Jacobio, CDE, IND, Approval, Combination Therapy, KRAS G12C, Cetuximab, China

Kazia Reports Positive Final Data From P-II Study of Paxalisib to Treat Patients with Glioblastoma

Published: Dec 6, 2021 | Tags: Kazia, P-II, Study, Paxalisib, Glioblastoma

Merck’s Keytruda (pembrolizumab) Receives the US FDA's approval to Treat Adult and Pediatric Patients with Stage IIB or IIC Melanoma

Published: Dec 6, 2021 | Tags: Merck, Keytruda, pembrolizumab, US, FDA, Approval, Stage IIB, IIC Melanoma

Related Post: PharmaShots Weekly Snapshots (November 29 -December 03, 2021)